A CHRONOBIOLOGICAL TREATMENT combining evening melatonin and morning light therapy IN IDIOPATHIC HYPERSOMNIA: a prospective, double bind, randomized, placebo-controlled -trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506663-33-00

Acronym

8443

Enrollment

Registered

2023-12-14

Start date

2024-09-07

Completion date

Unknown

Last updated

2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IDIOPATHIC HYPERSOMNIA

Brief summary

The primary endpoint is the difference in IHSS score before and after 6 weeks of active chronobiotherapy (2mg melatonin and BLT) or 6 weeks of placebo conditions (placebo drug and placebo light).

Interventions

DRUGCellulose microcristalline

DRUGMélatonine à libération immédiate

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the difference in IHSS score before and after 6 weeks of active chronobiotherapy (2mg melatonin and BLT) or 6 weeks of placebo conditions (placebo drug and placebo light).	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026